Gene and cell‐based therapies for inherited retinal disorders: An update
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Retinal degenerations present a unique challenge as disease progression is irreversible and the retina has little regenerative potential. No current treatments for inherited retinal disease have the ability to reverse blindness, and current dietary supplement recommendations only delay disease progression with varied results. However, the retina is anatomically accessible and capable of being monitored at high resolution in vivo. This, in addition to the immune‐privileged status of the eye, has put ocular disease at the forefront of advances in gene‐ and cell‐based therapies. This review provides an update on gene therapies and randomized control trials for inherited retinal disease, including Leber congenital amaurosis, choroideremia, retinitis pigmentosa, Usher syndrome, X‐linked retinoschisis, Leber hereditary optic neuropathy, and achromatopsia. New gene‐modifying and cell‐based strategies are also discussed. © 2016 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes
Gilbert, L. A., Larson, M. H., Morsut, L., Liu, Z., Brar, G. A., Torres, S. E., Stern-Ginossar, N., Brandman, O., Whitehead, E. H., Doudna, J. A., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.044 · Cited by 3,696 · cited 1×
“This strategy was shown to be applicable to eukaryotes, including human cells, when fused to transcription modulators [Gilbert et al., 2013; Maeder et al., 2013; Gilbert et al., 2014].”
BackgroundDouble nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
CRISPR-Cas systems for editing, regulating and targeting genomes
Sander, J. D., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2842 · Cited by 3,153
Hartong, D. T., Berson, E. L., & Dryja, T. P. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69740-7 · Cited by 2,924
Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation
Gilbert, L. A., Horlbeck, M. A., Adamson, B., Villalta, J. E., Chen, Y., Whitehead, E. H., Guimaraes, C., Panning, B., Ploegh, H. L., Bassik, M. C., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.029 · Cited by 2,728
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 2×
“…that has shown beneficial results in treating inherited retinal disease [Bainbridge et al., 2008; Cideciyan et al., 2008; Hauswirth et al., 2008; Maguire et al., 2008; Cideciyan et al., 2009; Maguire et al., 2009; Banin et al., 2010; Simonelli et al., 2010; Jacobson et al., 2012; Testa et al.,…”
BackgroundEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 2×
“…phase I/II gene therapy trials assessed the effects of unilateral, subretinal administration of AAV-RPE65, which demonstrated short-term rescue [Bainbridge et al., 2008; Cideciyan et al., 2008; Hauswirth et al., 2008; Maguire et al., 2008; Cideciyan et al., 2009; Maguire et al., 2009; Banin et…”
BackgroundSchwartz, S. D., Regillo, C. D., Lam, B. L., Eliott, D., Rosenfeld, P. J., Gregori, N. Z., Hubschman, J.-P., Davis, J. L., Heilwell, G., Spirn, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61376-3 · Cited by 1,327
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202 · cited 1×
“An AAV-mediated therapeutic gene delivery was used in a naturally occurring canine model for LCA2 (RPE65 / ) in 2001, which led to the long-term restoration of vision in treated dogs [Acland et al., 2001].”
Hamel, C. (2006) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-1-40 · Cited by 962
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Gene therapy using adeno-associated virus vectors
Daya, S., & Berns, K. I. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-08 · Cited by 926
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865 · cited 2×
“…results in treating inherited retinal disease [Bainbridge et al., 2008; Cideciyan et al., 2008; Hauswirth et al., 2008; Maguire et al., 2008; Cideciyan et al., 2009; Maguire et al., 2009; Banin et al., 2010; Simonelli et al., 2010; Jacobson et al., 2012; Testa et al., 2013; Boye and Boye, 2015].”
BackgroundMacLaren, R. E., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Seymour, L., Clark, K. R., During, M. J., Cremers, F. P. M., Black, G. C. M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62117-0 · Cited by 796 · cited 1×
“Two patients experienced two- and four-line improvements in visual acuity, and five patients had increases in mean retinal sensitivity despite detachment of the macula (NCT01461213) [MacLaren et al., 2014].”
Dalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734 · cited 1×
“2) since transduction theoretically occurs uniformly across the retina [Lebherz et al., 2008; Natkunarajah et al., 2008; Dalkara et al., 2013; Kay et al., 2013].”
Gal, A., Li, Y., Thompson, D. A., Weir, J., Orth, U., Jacobson, S. G., Apfelstedt-Sylla, E., & Vollrath, D. (2000) · Nature Genetics · doi:10.1038/81555 · Cited by 679
Genome Engineering with Targetable Nucleases
Carroll, D. (2014) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060713-035418 · Cited by 568 · cited 5×
“The Xanthomonas plant bacteria species integrates its DNA into its host genome by way of transcription activator-like endonucleases (TALs) [Carroll, 2014; Gilles and Averof, 2014].”
InfluentialPositional cloning of the gene associated with X-linked juvenile retinoschisis
Sauer, C. G., Gehrig, A., Warneke-Wittstock, R., Marquardt, A., Ewing, C. C., Gibson, A., Lorenz, B., Jurklies, B., & Weber, B. H. F. (1997) · Nature Genetics · doi:10.1038/ng1097-164 · Cited by 497 · cited 1×
“Mutations in retinoschisin (RS1), a gene encoding a protein thought to be important for retinal cell layer organization and synapse structure, were identified by positional cloning as the cause of XLRS (Table I) [Sauer et al., 1997; Weber et al., 2002].”
Bennett, J., Wellman, J., Marshall, K. A., McCague, S., Ashtari, M., DiStefano-Pappas, J., Elci, O. U., Chung, D. C., Sun, J., Wright, J. F., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30371-3 · Cited by 461 · cited 1×
“…safety of vector administration to the contralateral eyewas reported in eleven patients, confirming a previous study with fewer patients [Bennett et al., 2012] and representing the first ocular gene therapy to be successfully delivered to the previously untreated eye [Bennett et al., 2016].”
ResultAlgvere, P. V., Berglin, L., Gouras, P., & Sheng, Y. (1994) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/bf00184273 · Cited by 346 · cited 1×
“In the early 1990s, adult and fetal RPE tissue was first transplanted in patients with end-stage age-related macular degeneration (AMD) to replace diseased RPE [Peyman et al., 1991; Algvere et al., 1994].”
Allocca, M., Doria, M., Petrillo, M., Colella, P., Garcia-Hoyos, M., Gibbs, D., Kim, S. R., Maguire, A., Rex, T. S., Di Vicino, U., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34316 · Cited by 292
Correction of the retinal dystrophy phenotype of the RCS rat by viral gene transfer of Mertk
Vollrath, D., Feng, W., Duncan, J. L., Yasumura, D., D'Cruz, P. M., Chappelow, A., Matthes, M. T., Kay, M. A., & LaVail, M. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.221364198 · Cited by 290 · cited 2×
“Several studies have tested the efficacy of gene therapy in the Royal College of Surgeons (RCS) rat, which was found to carry a Mertk mutation [Vollrath et al., 2001; Smith et al., 2003; Tschernutter et al., 2005; Conlon et al., 2013].”
Effective delivery of large genes to the retina by dual AAV vectors
Trapani, I., Colella, P., Sommella, A., Iodice, C., Cesi, G., de Simone, S., Marrocco, E., Rossi, S., Giunti, M., Palfi, A., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201302948 · Cited by 269
Beltran, W. A., Cideciyan, A. V., Lewin, A. S., Iwabe, S., Khanna, H., Sumaroka, A., Chiodo, V. A., Fajardo, D. S., Román, A. J., Deng, W.-T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118847109 · Cited by 260
Ghazi, N. G., Abboud, E. B., Nowilaty, S. R., Alkuraya, H., Alhommadi, A., Cai, H., Hou, R., Deng, W.-T., Boye, S. L., Almaghamsi, A., et al. (2016) · Human Genetics · doi:10.1007/s00439-016-1637-y · Cited by 243 · cited 1×
“Safety was confirmed in preclinical studies in monkeys, and a phase I open-label, dose-escalation trial involving subretinal injection of rAAV2VMD2-hMERTK to six patients with advanced MERTK-associated RP was initiated [Ghazi et al., 2016].”
BackgroundGene Therapy for Leber Hereditary Optic Neuropathy
Feuer, W. J., Schiffman, J. C., Davis, J. L., Porciatti, V., Gonzalez, P., Koilkonda, R. D., Yuan, H., Lalwani, A., Lam, B. L., & Guy, J. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2015.10.025 · Cited by 230 · cited 1×
“Initial results published in November 2015 reported no serious safety issues in the first five patients enrolled and increased visual acuity in two of five patients following the delivery of the therapeutic gene [Feuer et al., 2016].”
Peyman, G. A., Blinder, K. J., Paris, C. L., Alturki, W., Nelson, N. C., & Desai, U. (1991) · Ophthalmic Surgery, Lasers and Imaging Retina · doi:10.3928/1542-8877-19910201-12 · Cited by 227
Jacobson, S. G., Acland, G. M., Aguirre, G. D., Aleman, T. S., Schwartz, S. B., Cideciyan, A. V., Zeiss, C. J., Komaromy, A. M., Kaushal, S., Roman, A. J., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.005 · Cited by 224 · cited 1×
“Following the landmark findings of Acland et al., safety studies for RPE65 delivery by AAV2 were performed in RPE65-mutant canines and normal non-human primates [Jacobson et al., 2006a,b].”
ResultEfficacy and Safety of rAAV2-ND4 Treatment for Leber’s Hereditary Optic Neuropathy
Wan, X., Pei, H., Zhao, M.-J., Yang, S., Hu, W.-K., He, H., Ma, S.-Q., Zhang, G., Dong, X.-Y., Chen, C., et al. (2016) · Scientific Reports · doi:10.1038/srep21587 · Cited by 182 · cited 7×
“Preliminary findings showed that eyes tolerated the transplant, and cellular adaptive optics OCT imaging suggested incorporation of the transplanted cells into the macula [Park et al., 2015].”
InfluentialTargeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors
Kay, C. N., Ryals, R. C., Aslanidi, G. V., Min, S. H., Ruan, Q., Sun, J., Dyka, F. M., Kasuga, D., Ayala, A. E., Van Vliet, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062097 · Cited by 168 · cited 1×
“2) since transduction theoretically occurs uniformly across the retina [Lebherz et al., 2008; Natkunarajah et al., 2008; Dalkara et al., 2013; Kay et al., 2013].”
BackgroundNatkunarajah, M., Trittibach, P., McIntosh, J., Duran, Y., Barker, S. E., Smith, A. J., Nathwani, A. C., & Ali, R. R. (2008) · Gene Therapy · doi:10.1038/sj.gt.3303074 · Cited by 138 · cited 1×
“2) since transduction theoretically occurs uniformly across the retina [Lebherz et al., 2008; Natkunarajah et al., 2008; Dalkara et al., 2013; Kay et al., 2013].”
BackgroundDyka, F. M., Boye, S. L., Chiodo, V. A., Hauswirth, W. W., & Boye, S. E. (2014) · Human Gene Therapy Methods · doi:10.1089/hgtb.2013.212 · Cited by 128
Banin, E., Gootwine, E., Obolensky, A., Ezra-Elia, R., Ejzenberg, A., Zelinger, L., Honig, H., Rosov, A., Yamin, E., Sharon, D., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.114 · Cited by 113 · cited 1×
“…deficiency), canine models of CNGB3 deficiency, and a sheep model of CNGA3 deficiency have been treated with gene replacement, yielding increased visual function [Alexander et al., 2007; Komaromy et al., 2010; Michalakis et al., 2010; Carvalho et al., 2011; Pang et al., 2012; Banin et al., 2015].”
BackgroundRetinoschisin gene therapy in photoreceptors, Müller glia or all retinal cells in the Rs1h−/− mouse
Byrne, L. C., Öztürk, B. E., Lee, T., Fortuny, C., Visel, M., Dalkara, D., Schaffer, D. V., & Flannery, J. G. (2014) · Gene Therapy · doi:10.1038/gt.2014.31 · Cited by 96 · cited 3×
“X-Linked Retinoschisis (XLRS) XLRS is a retinal degeneration affecting between 1 in 5,000 to 25,000 individuals worldwide [Byrne et al., 2014].”
BackgroundYe, G.-J., Budzynski, E., Sonnentag, P., Miller, P. E., Sharma, A. K., Ver Hoeve, J. N., Howard, K., Knop, D. R., Neuringer, M., McGill, T., et al. (2015) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2015.076 · Cited by 53
Cwerman-Thibault, H., Augustin, S., Ellouze, S., Sahel, J.-A., & Corral-Debrinski, M. (2014) · Comptes Rendus. Biologies · doi:10.1016/j.crvi.2013.11.011 · Cited by 49
CRISPR/Cas9-Mediated Phage Resistance Is Not Impeded by the DNA Modifications of Phage T4
Yaung, S. J., Esvelt, K. M., & Church, G. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098811 · Cited by 39 · cited 1×
“Unlike TALEN,CRISPR/Cas has been shown to be unaffected by DNA methylation status [Hsu et al., 2013; Ran et al., 2013b; Yaung et al., 2014].”
BackgroundMyosin7a Deficiency Results in Reduced Retinal Activity Which Is Improved by Gene Therapy
Colella, P., Sommella, A., Marrocco, E., Di Vicino, U., Polishchuk, E., Garrido, M. G., Seeliger, M. W., Polishchuk, R., & Auricchio, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072027 · Cited by 34
Cited by
Garafalo, A. V., Cideciyan, A. V., Héon, E., Sheplock, R., Pearson, A., WeiYang Yu, C., Sumaroka, A., Aguirre, G. D., & Jacobson, S. G. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.100827 · Cited by 173
Gene therapy and genome surgery in the retina
DiCarlo, J. E., Mahajan, V. B., & Tsang, S. H. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120429 · Cited by 127
Self-citationGene therapy for age-related macular degeneration
Moore, N. A., Bracha, P., Hussain, R. M., Morral, N., & Ciulla, T. A. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1356817 · Cited by 63
“Genetic therapy has been investigated in inherited retinal diseases such as Leber’s congential amaurosis (LCA), choroideremia, retinitis pigmentosa (RP), Usher’s disease, Stargardt’s disease, Leber’s hereditary optic neuropathy, achromatopsia, and X-linked retinoschisis [11].”
BackgroundCiulla, T. A., Hussain, R. M., Berrocal, A. M., & Nagiel, A. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1740676 · Cited by 59
Kovacs, K. D., Ciulla, T. A., & Kiss, S. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2121646 · Cited by 20
Metadata
- Authors
- Sengillo, J. D., Justus, S., Tsai, Y., Cabral, T., & Tsang, S. H.
- Venue
- American Journal of Medical Genetics Part C: Seminars in Medical Genetics
- Publisher
- Wiley
- Published
- 2016-11-08
- Volume
- 172
- Issue
- 4
- Pages
- 349-366
- ISSN
- 1552-4868 (ISSN-L)
- 1552-4876
- OpenAlex
- W2556045776
- Cited by
- 65
- References
- 38
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.